Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
4
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
inclisiran
new york
new york blog main
new york top stories
regeneron pharmaceuticals
sanofi
alnylam pharmaceuticals
biotech
cholesterol
deals
pcsk9
pcsk9 inhibitors
praluent
repatha
san francisco blog main
san francisco top stories
the medicines co.
alirocumab
cancer
cancer drugs
cobimetinib
data
evolocumab
fda
investing
ipo
ldl
mark timney
mt sinai hospital
novartis
peter wijngaard
prashant vaishnava
revolution medicines
What
drug
4
×
medicines
4
×
cholesterol
medco
fda
lowering
twice
aces
acquire
agreed
announced
big
billion
bringing
brings
cancer
cash
ceo
clears
closer
company
compound
deal
despite
family
filing
flexible
hardest
hit
hottest
hunters
inched
inclisiran
ipo
key
market
meant
medicine
morning
nasdaq
Language
unset
4
×
Current search:
drug
×
unset
×
medicines
×
amgen
×
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing